CG Oncology President & COO Bellete to depart June 30; CEO Kuan becomes President

CG Oncology, Inc.

Ambaw Bellete, President & COO, agreed to separation effective June 30, 2026; severance per existing employment agreement.
Arthur Kuan appointed as President in addition to his other roles, effective upon Bellete's departure.
Company has initiated a search for a Chief Commercial Officer.
No reason for departure given; transition appears orderly.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-237908
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2026-05-26T12:00:15+00:00
discovered_at: 2026-05-26T12:05:00.340648+00:00
generated_at: 2026-05-26T12:11:05.047967+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-237908
json_url: https://secwatch.observer/filing/0001193125-26-237908.json
markdown_url: https://secwatch.observer/filing/0001193125-26-237908.md
text_url: https://secwatch.observer/filing/0001193125-26-237908.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/0001193125-26-237908-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526237908/ck0001991792-20260520.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Arthur Kuan

President

CGON · CG Oncology, Inc.

Effective: 2026-06-30
Filed: May 26, 2026 12:00 UTC

On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.

Departed

Ambaw Bellete

President & Chief Operating Officer

CGON · CG Oncology, Inc.

Effective: 2026-06-30
Successor: Arthur Kuan
Filed: May 26, 2026 12:00 UTC

On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.

Source-grounded claims

1b56bdd249

Arthur Kuan was appointed as President at CG Oncology, Inc..

On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

69a3f0621d

Ambaw Bellete departed as President & Chief Operating Officer at CG Oncology, Inc..

On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR

accession 0001193125-26-237908

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.